Protara Therapeutics closes $100 million public offering for clinical development and corporate purposes.

From GlobeNewswire: 2024-12-11 16:05:00

Protara Therapeutics, Inc. closed a public offering, selling 13,690,000 shares of common stock at $6.25 per share and pre-funded warrants for 2,325,372 shares at $6.249 per warrant. The offering raised approximately $100 million before expenses. The proceeds will fund clinical development of TARA-002 and other programs, along with general corporate purposes. TD Cowen, Cantor, LifeSci Capital, Oppenheimer & Co., and Scotiabank managed the offering. The shares were issued under an effective shelf registration statement. This press release contains forward-looking statements. For more information, contact Justine O’Malley at Protara Therapeutics.



Read more at GlobeNewswire: Protara Announces Closing of $100 Million Public Offering